Invitrogen Signs Deal to Acquire Dynal Biotech

Invitrogen has signed a definitive agreement to acquire privately held molecular separation and purification technology pioneer Dynal Biotech from majority owner Nordic Capital and a co-investor for approximately NOK 2.5 billion. Dynal is the industry leader in magnetic bead technologies that are used in cell separation and purification, cell stimulation, protein research, nucleic acid research and microbiology.

Pharmabiz (http://www.pharmabiz.com/article/detnews.asp?articleid=26115§ionid=)